BRIEF published on 06/06/2024 at 13:05, 2 years 5 months ago Theralase détruit avec succès le cancer du poumon Technologies Théralase Cancer Du Poumon Rutherrin® Étude Préclinique
PRESS RELEASE published on 06/06/2024 at 13:00, 2 years 5 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 2 years 5 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
BRIEF published on 06/04/2024 at 13:05, 2 years 5 months ago Technologie Theralase® efficace pour l'inactivation des virus Theralase Ruvidar Recherche Antivirale Heliyon Inactivation Des Virus
PRESS RELEASE published on 06/04/2024 at 13:00, 2 years 5 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
BRIEF published on 05/30/2024 at 13:05, 2 years 5 months ago Theralase Releases 1Q2024 Financial Statements Financial Results Cancer Treatment Theralase Study II PDCs
BRIEF published on 05/30/2024 at 13:05, 2 years 5 months ago Theralase publie ses états financiers du 1T2024 Résultats Financiers Traitement Du Cancer Theralase Étude II PDC
PRESS RELEASE published on 05/30/2024 at 13:00, 2 years 5 months ago Theralase(R) Release's 1Q2024 Financial Statements Theralase® releases unaudited interim consolidated 1Q2024 financial statements. Company to host conference call on June 6th, 2024. Study II update and Break Through Designation progress discussed Conference Call Financial Statements Break Through Designation Theralase Study II
BRIEF published on 04/24/2024 at 13:05, 2 years 6 months ago Theralase Technologies Inc. Completes $750,200 Funding Round Private Placement Pharmaceuticals Clinical Research Investment Theralase Technologies
BRIEF published on 04/24/2024 at 13:05, 2 years 6 months ago Theralase Technologies Inc. finalise une ronde de financement de 750 200 $ Investissement Placement Privé Médicaments Recherche Clinique Technologies Théralase
Published on 11/20/2026 at 15:00, 17 hours 50 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 18 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 18 hours 50 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 19 hours 20 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 19 hours 20 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 9 hours 5 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 22:39, 10 hours 10 minutes ago ABIVAX: Abivax publie une déclaration concernant le rapport d'un vendeur à découvert
Published on 11/20/2026 at 21:36, 11 hours 14 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 20:49, 12 hours 1 minute ago E-PANGO: Jugement du Tribunal Judiciaire de Paris relatif au contentieux avec le groupement RIVP-HENEO-HSF
Published on 11/20/2026 at 18:34, 14 hours 15 minutes ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 14 hours 15 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 15 hours 15 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 15 hours 15 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 13 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR